Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
JetBlue Airways Corporation (JBLU) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JetBlue Airways Corporation (JBLU) - free report >>
Image: Bigstock
New Strong Sell Stocks for September 8th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Adverum Biotechnologies, Inc. (ADVM - Free Report) is a clinical-stage gene therapy company. The Zacks Consensus Estimate for its current year earnings has been revised 16.3% downward over the last 30 days.
JetBlue Airways Corporation (JBLU - Free Report) is a provider of air transportation services. The Zacks Consensus Estimate for its current year earnings has been revised 0.2% downward over the last 30 days.
Kadmon Holdings, Inc. is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 10% downward over the last 30 days.
Alpine Immune Sciences, Inc. (ALPN - Free Report) is focussed on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
Provention Bio, Inc. is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 37.7% downward over the last 30 days.
View the entire Zacks Rank #5 List.